Chloroquine Phosphate 500mg Tablets

chlorquine-phosphate-tablets
  • Dosage: Chloroquine Phosphate 500mg
  • Packaging: 25 tablets/blister*1/box
  • Shelf Life: 36months 

Click to add this item to cart.

Product Description

Product NameChloroquine Phosphate Tablets (Chloroquine Phosphate 500mg Oral Tablets)
SpecificationEach tablet contains: Chloroquine Phosphate 500mg (equivalent to Chloroquine Base approximately 300mg)
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientChloroquine Phosphate
Pharmacological Class4-Aminoquinoline Antimalarial / Antirheumatic Agent
Route of AdministrationOral administration (swallowed whole with water). May be taken with meals or milk to reduce gastrointestinal upset. Take at approximately the same time each day.
PackagingBlister pack (PVC-Alu) or HDPE bottle, typically 10 or 30 tablets per blister pack or bottle
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Shelf Life36 months (unopened)

Product Overview

Chloroquine Phosphate Tablets is an oral preparation containing Chloroquine Phosphate 500mg per film-coated tablet. Chloroquine is a 4-aminoquinoline derivative used primarily for the prophylaxis and treatment of malaria caused by susceptible Plasmodium species, as well as for the management of certain autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus. The product is formulated as film-coated tablets for convenient oral administration.

Chloroquine Phosphate 500mg Tablets: What the Published Guidance Says

Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.

Chloroquine Phosphate 500mg Tablets sits in the Malaria & ACTs range. The notes below are the ones that most often change a specification, a label or a tender submission.

  • The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
  • ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
  • For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual

These points are quoted because they shape how Chloroquine Phosphate 500mg Tablets is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.

Ordering Parameters for Chloroquine Phosphate 500mg Tablets

Product NameChloroquine Phosphate Tablets (Chloroquine Phosphate 500mg Oral Tablets)
SpecificationEach tablet contains: Chloroquine Phosphate 500mg (equivalent to Chloroquine Base approximately 300mg)
Dosage FormOral Film-Coated Tablet (for oral administration)
Active IngredientChloroquine Phosphate
Pharmacological Class4-Aminoquinoline Antimalarial / Antirheumatic Agent
Route of AdministrationOral administration (swallowed whole with water). May be taken with meals or milk to reduce gastrointestinal upset. Take at approximately the same time each day.
StorageStore below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze.
Therapeutic groupMalaria & ACTs — Malaria & ACTs
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg, Artesunate 200mg + Amodiaquine 600mg Tablets, Artesunate 400mg Mefloquine 500mg Tablets, Artemether Lumefantrine 80/480mg Tablets, Artesunate Suppositories 100mg, Artemether 80mg Injection.

Pharmacopoeial Standard, Release Testing & COA

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Chloroquine Phosphate 500mg Tablets is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

The quality control package for the marketed pack covers:

  • Testing for dissolution or release profile (solid oral forms)
  • Testing for uniformity of dosage units
  • Testing for water content and pH where applicable
  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)
  • Testing for heavy metals and elemental impurities

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

Packing, Labelling Languages & Export Paperwork

  • Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 10 or 30 tablets per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
  • Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
  • Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
  • Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.

Marketing Authorisation & Tender Support

Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.

  • Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
  • Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
  • Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
  • Batch manufacturing and packaging records released for inspection on request during supplier audits.
  • Re-test or renewal support when the marketing authorisation comes up for variation or renewal.

This page describes Chloroquine Phosphate 500mg Tablets as a product of the ACT regimens named in the WHO Model List of Essential Medicines family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.

Chloroquine Phosphate 500mg Tablets: Common Procurement Questions

What pack size is available for Chloroquine Phosphate 500mg Tablets?

The reference pack is Blister pack (PVC-Alu) or HDPE bottle, typically 10 or 30 tablets per blister pack or bottle. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.

What documentation comes with a shipment of Chloroquine Phosphate 500mg Tablets?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months.

Does the batch documentation for Chloroquine Phosphate 500mg Tablets support a registration filing?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

Can you support registration in my market?

We provide COA, HPLC and GC analytical data, stability data, DMF and dossier packages together with registration support documents. DML Number Jin20160068 covers our medicines production.

What is the difference between artesunate and artemether for injection?

Artesunate is the WHO drug of choice for severe malaria and may be given intravenously or intramuscularly at 2.4 mg/kg. Artemether is an alternative given intramuscularly at 3.2 mg/kg on admission then 1.6 mg/kg daily, and must never be given intravenously.

Products Commonly Ordered with Chloroquine Phosphate 500mg Tablets

Browse the full Malaria & ACTs range; all Tablets; the complete product catalogue.

Request a Quotation for Chloroquine Phosphate 500mg Tablets

Send the specification, pack size, quantity and destination market for Chloroquine Phosphate 500mg Tablets 500mg and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products